Catalog No.
DHB94401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
Fab'-IgG1-kappa
Clonality
Monoclonal
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein L purified from cell culture supernatant.
Accession
P01375
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDP870, PHA-738144, Certolizumab pegol, CAS: 428863-50-7
Clone ID
Certolizumab
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis, PMID: 32207094
[Certolizumab], PMID: 31208736
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT), PMID: 29660425
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis, PMID: 31917928
Certolizumab pegol, PMID: 20190560
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation, PMID: 27140438
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2), PMID: 29660421
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review, PMID: 33135826
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database, PMID: 29623679
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study, PMID: 29030361
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis, PMID: 30848558
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction, PMID: 32381562
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials, PMID: 31245056
Certolizumab pegol for the treatment of psoriasis, PMID: 28165828
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis, PMID: 30943133
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2), PMID: 32652544
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, PMID: 30772098
Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases, PMID: 27704400
Certolizumab for rheumatoid arthritis, PMID: 24447441
Long-term efficacy of certolizumab pegol for psoriasis, PMID: 32951203
Certolizumab pegol for treating axial spondyloarthritis, PMID: 27366922
Certolizumab pegol-induced palmoplantar pustulosis: A case report and review of the literature, PMID: 29370988
Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy, PMID: 33124565
ACG Clinical Guideline: Management of Crohn's Disease in Adults, PMID: 29610508
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA, PMID: 28498975
Certolizumab Pegol-Induced Heart Failure, PMID: 29232326
Certolizumab-induced facial eruption in a pregnant woman with severe Behcet's disease, PMID: 32770724
Certolizumab pegol: in rheumatoid arthritis, PMID: 19894782
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults, PMID: 21328299
Certolizumab pegol: a review of its use in the management of rheumatoid arthritis, PMID: 23338540
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults, PMID: 28884785
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, PMID: 27863807
Improvement of Certolizumab Fab' properties by PASylation technology, PMID: 33116155
Certolizumab pegol for the treatment of psoriatic arthritis, PMID: 25651776
[Certolizumab pegol], PMID: 21794764
Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis, PMID: 24919863
Certolizumab pegol in axial spondyloarthritis, PMID: 24215406
Certolizumab pegol in Crohn's disease, PMID: 19180261
Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease, PMID: 20118143
Certolizumab pegol: in Crohn's disease, PMID: 17516714
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation, PMID: 31498069
Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy, PMID: 33247833
Certolizumab pegol for the management of Crohn's disease in adults, PMID: 19695385
Certolizumab pegol for induction of remission in Crohn's disease, PMID: 31476018
Certolizumab pegol in the treatment of Crohn's disease, PMID: 23451881
Certolizumab pegol, PMID: 18670430
Patient Satisfaction with CIMZIA ® (Certolizumab Pegol) AutoClicks ® in the UK, PMID: 32124272
Profile of certolizumab and its potential in the treatment of psoriatic arthritis, PMID: 23620660
Certolizumab pegol: a new biologic targeting rheumatoid arthritis, PMID: 20979550
Certolizumab pegol in the treatment of Takayasu arteritis, PMID: 30010945
For research use only. Not for human or drug use.
